CRL COO gifts 328 shares of common stock

CHARLES RIVER LABORATORIES INTERNATIONAL, INC. executive Birgit Girshick, Corporate Executive VP & COO, reported an indirect bona fide gift of 328 shares of common stock on March 4, 2026.

Rhea-AI Filing Summary

CHARLES RIVER LABORATORIES INTERNATIONAL, INC. executive Birgit Girshick, Corporate Executive VP & COO, reported an indirect bona fide gift of 328 shares of common stock on March 4, 2026. The gifted shares were held indirectly through a revocable trust and transferred at a reported price of $0.00 per share, reflecting a non-sale disposition.

After this gift, indirect holdings through the revocable trust were reported as 40,417 shares of common stock, while direct holdings were reported as 31,638 shares. A footnote explains that the indirect total includes shares previously reported as directly held, which are now correctly classified as indirectly held.

Insider Trade Summary

328 shares gifted

Gift 2 txns

Insider Girshick Birgit

Role Corporate Executive VP & COO

Type	Security	Shares	Price	Value
Gift	Common Stock	328	$0.00	$0.00
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 40,417 shares (Indirect, Revocable Trust); Common Stock — 31,638 shares (Direct)

Footnotes (1)

1. F1. Includes shares that were previously reported as directly held, which are now correctly reported as indirectly held.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Birgit Girshick report for CRL on March 4, 2026?

Birgit Girshick reported a bona fide gift of 328 shares of CHARLES RIVER LABORATORIES common stock. The transaction was an indirect disposition through a revocable trust, recorded at a price of $0.00 per share, indicating a non-sale transfer.

How many CRL shares did Birgit Girshick gift and what was the price per share?

She gifted 328 shares of CHARLES RIVER LABORATORIES common stock at a reported price of $0.00 per share. This reflects a bona fide gift transaction, not an open-market sale or purchase, and was reported as an indirect transaction via a revocable trust.

How many CHARLES RIVER LABORATORIES (CRL) shares does Birgit Girshick hold after the reported gift?

Following the reported gift, Birgit Girshick’s filings show 40,417 shares of common stock held indirectly through a revocable trust and 31,638 shares held directly. These figures represent her reported beneficial ownership positions after the March 4, 2026 transaction.

Was Birgit Girshick’s March 4, 2026 CRL transaction a sale or a gift?

The March 4, 2026 transaction was a bona fide gift, not a sale. It is coded as a G transaction, described as a bona fide gift, with 328 shares of common stock transferred indirectly from a revocable trust at $0.00 per share.

What does the revocable trust holding mean in Birgit Girshick’s CRL Form 4 filing?

The filing shows indirect ownership of shares through a revocable trust. After the gift, the trust held 40,417 shares. A footnote states these indirect holdings include shares previously reported as directly held, now correctly classified as indirectly owned through the trust.

Did Birgit Girshick update both direct and indirect CRL holdings in this Form 4?

Yes. The Form 4 reports an indirect gift of 328 shares via a revocable trust and shows updated totals of 40,417 indirect and 31,638 direct shares. A footnote clarifies that some shares were reclassified from direct to indirect ownership in the latest reporting.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/05/2026 - 05:18 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Girshick Birgit

(Last) (First) (Middle)

C/O CHARLES RIVER LABORATORIES

251 BALLARDVALE STREET

(Street)

WILMINGTON MA 01887

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. [ CRL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Corporate Executive VP & COO

3. Date of Earliest Transaction (Month/Day/Year)
03/04/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/04/2026		G		328	D	$0	40,417(1)	I	Revocable Trust
Common Stock								31,638	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Includes shares that were previously reported as directly held, which are now correctly reported as indirectly held.

	/s/ Birgit Girshick	03/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.